Last €41.32 EUR
Change Today +0.71 / 1.75%
Volume 0.0
HOS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 2:16 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HOS) Snapshot

Open
€41.35
Previous Close
€40.61
Day High
€41.36
Day Low
€41.32
52 Week High
07/31/14 - €42.33
52 Week Low
10/4/13 - €28.22
Market Cap
7.0B
Average Volume 10 Days
16.3
EPS TTM
--
Shares Outstanding
168.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HOS)

hospira inc (HOS) Details

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

17,000 Employees
Last Reported Date: 02/12/14
Founded in 2003

hospira inc (HOS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $464.7K
Senior Vice President of Operations
Total Annual Compensation: $432.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $444.6K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $429.8K
Compensation as of Fiscal Year 2013.

hospira inc (HOS) Key Developments

Hospira Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Hospira Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $1,135.8 million against $1,026.2 million a year ago. Income from operations was $99.5 million against $52.2 million a year ago. Income before income taxes was $81.1 million against $22.2 million a year ago. Net income was $70.9 million or $0.42 per basic and diluted share against $32.9 million or $0.20 per basic and diluted share a year ago. Adjusted income from operations was $179.3 million against $126.4 million a year ago. Adjusted net income was $122.1 million or $0.72 per diluted share against $92.1 million or $0.55 per diluted share a year ago. For the six months, the company reported net sales of $2,186.6 million against $1,910.2 million a year ago. Income from operations was $199.1 million against loss from operations of $66.4 million a year ago. Income before income taxes was $162.2 million against loss before income taxes of $118.3 million a year ago. Net income was $138.8 million or $0.82 per diluted share against net loss of $43.7 million or $0.26 per basic and diluted share a year ago. Adjusted Net Sales were $2,186.6 million against $2,014.5 million a year ago. Adjusted income from operations was $330.8 million against $227.6 million a year ago. Adjusted net income was $223.8 million or $1.32 per diluted share against $178.2 million or $1.07 per diluted share a year ago. Net Cash provided by operating activities was $175.5 million compared to $50.6 million a year ago. Purchases of intangibles and other investments were $4.3 million compared to $9.9 million a year ago. For fiscal 2014, the company now expects net sales growth to range between 6% and 9% on a constant-currency basis, with minimal impact from foreign currency. The company is now projecting adjusted diluted earnings per share to range between $2.30 and $2.50. Cash flow from operations is expected to range between $275 million and $375 million. Capital expenditure projections remain in a range between $375 million and $425 million. The company continues to expect depreciation and amortization to range between $225 million and $275 million.

Hospira Reportedly In Talks To Acquire Medical Nutrition Business

Danone (ENXTPA:BN) is in talks to sell its medical nutrition business to Hospira Inc. (NYSE:HSP). The negotiations have been going on for several weeks and, according to people familiar with the situation, both the parties are discussing the terms of a potential cash and stock deal that would value the business at close to $5 billion. The people cautioned that the talks were ongoing and no deal was certain, however. Nestlé S.A. (SWX:NESN) and Fresenius SE & Co KGaA (DB:FRE), had been interested in the medical nutrition business. However, it is not yet clear if they are still interested in the acquisition. JPMorgan has been hired by Danone to handle the sale process. Financial Times added that Danone and Hospira were not immediately available for comment.

Hospira Inc. to Report Q2, 2014 Results on Jul 30, 2014

Hospira Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HOS:GR €41.32 EUR +0.71

HOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $44.91 USD -0.02
Cintas Corp $65.96 USD +0.07
Grifols SA €33.75 EUR -0.21
Terumo Corp ¥2,605 JPY +10.00
Varian Medical Systems Inc $84.23 USD -0.46
View Industry Companies
 

Industry Analysis

HOS

Industry Average

Valuation HOS Industry Range
Price/Earnings 51.9x
Price/Sales 2.1x
Price/Book 2.8x
Price/Cash Flow 52.2x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.